Well looking back at the New Myer strategy pres from 2 years ago. Nordstrum and Macy's were flying high at that time, but the SP has halved since then, Hudson's bay is worse.
Myr said they would be focussing on sales per sq meter, and sadly that went backwards from q1 to q2 from 6% to 5.6% in the most critical quarter of the year.
They also are focusing on concessions which is working well, but their tightened Myer Exclusives brands is doing terribly from what I can see. As the concession sales are increasing in the product mix, that will boost margins, as Myer sort of clips the ticket, rather than having the cost of stock etc in these (correct me if I am wrong). So I don't really think the margin improvement is anything to get excited about in the context of the sales mix.
The problem MYR has is that it is in a strategically weak position with the sales mix they have, as the better a concession does, the more tempting it might be for them to step out on their own at the expiry of the deal, whereas Myer exclusives are strategically strong as customers can't go anywhere else for them, whatever they are. The concessions strategy would be far better if MYR owned the real estate, rather then being a tenant.
So IMO the good news on margins isn't really good, with such a slight increase, the strategic situation is worse, and Comparables, and sales per square meter were comparably awful over xmas. The main good news is the dividend, and that they have improved earnings on pcp.
Shorted the open based on that, for a quickie. Might short again towards the XD if the market gets too excited about the 3c ff.
- Forums
- ASX - By Stock
- MYR
- The longing of the shorts
MYR
myer holdings limited
Add to My Watchlist
1.65%
!
61.5¢

The longing of the shorts, page-56
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
61.5¢ |
Change
0.010(1.65%) |
Mkt cap ! $1.062B |
Open | High | Low | Value | Volume |
60.0¢ | 62.5¢ | 59.8¢ | $3.415M | 5.582M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 19696 | 61.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
62.5¢ | 92228 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6118 | 0.605 |
13 | 319011 | 0.600 |
7 | 60403 | 0.595 |
18 | 222579 | 0.590 |
10 | 91829 | 0.585 |
Price($) | Vol. | No. |
---|---|---|
0.630 | 120060 | 4 |
0.635 | 66114 | 2 |
0.640 | 8130 | 1 |
0.645 | 10000 | 1 |
0.650 | 91182 | 7 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
MYR (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online